SCIMEGA - Key Persons
Job Titles:
- Co - Founding Partner / Co - Owner
In 1997, Andrée along with her business partner Denise Deakin launched Scimega, Canada's first oncology CRO. In her role as General Manager Andrée's unwavering vision was to develop the high caliber business operations necessary for Scimega's success as Canada's premier oncology CRO. Together with Denise, she crafted business strategies & leveraged opportunities. Today, Andrée remains a partner at Scimega with an active interest in the company's long term success.
Job Titles:
- in 2006 As a Clinical Research Associate
- Vice President Quality & Compliance
Catherine currently serves as Scimega's Vice President of Quality and Compliance. She has over 19 years of experience in complex clinical research and ICH GCP regulated and global environments. Dedicated to the successful conduct of oncology clinical trials in Canada Catherine ensures the effectiveness and continuous improvement of Scimega's quality management system, aligned with the regulations. She is responsible for building a talented, qualified workforce at the company with continued enhanced performance aligned with Scimega's mission and proactive quality culture. She also oversees the conduct of audits activities and GCP compliance consulting services at Scimega.
Catherine joined Scimega in 2006 as a Clinical Research Associate and has served several roles in the organisation in the clinical operations, human resources and quality & compliance departments. Prior to joining Scimega, Catherine worked mainly in medical research, notably in oncology clinical research, in both hospital and biopharmaceutical settings.
Catherine is a RQAP-GCP and lean certified professional. She holds a Master of Science in Neurosciences from University of Montreal and is a member of Scimega's Board of Directors.
Job Titles:
- Business Partner
- Co - Founding Partner / Co - Owner
In 1997, Denise along with her business partner of 22 years, Andrée Marceau, launched Scimega, Canada's first oncology CRO. Denise's unwavering vision was to position Scimega as a unique Canadian CRO fully dedicated to the clinical development of novel oncology compounds. In her role as President, Denise's primary focus was on developing successful business strategies, leveraging opportunities and overseeing the company's business development initiatives. Today, Denise remains a partner in the business with an active interest in Scimega's long term success.
In this interview, Dr. Quincy Chu, Medical Oncologist at the Cross Cancer Institute in Edmonton Alberta, discusses the ways in which targeted therapeutics have affected how clinical trials are now conducted, and how increased collaboration among several early phase investigative sites in Canada has led to higher enrolment for several trials.
He also offers advice to oncology sponsors on how they can improve collaboration with sites to speed up start-up times. You will hear why Canada's centralized healthcare system is ideally suited for both novel, early phase trials as well as for expansion of Phase III trials facing recruitment hurdles in the United States.
Geneviève currently serves as the Director of Finance and is responsible for all financial aspects of the company. In addition, she also oversees all the IT requirements for the company.
Geneviève joined Scimega in 2010 and brings over 13 years of experience in accounting, financial analysis and payroll administration. In her role as Director of Finance, she is responsible for leading the finance organization and supporting strategic planning and business operations. As a member of the Board of Directors, she also supports planning and execution of enhancements to support company growth.
Job Titles:
- Executive Director of Ontario Cancer Research Ethics Board
- Executive Director of the Ontario Cancer Research Ethics Board
In this interview Janet Manzo, Executive Director of the Ontario Cancer Research Ethics Board, discusses the development of a province-wide ethics review system for multi-centre clinical trials, as well as the advantages of initiatives like the Standard Consent Template, which promotes the harmonization of administrative processes and platforms.
She also explains how this allows one applicant to submit all study-wide post-approval applications on behalf of all participating centres, and how the ability for sponsors or CROs to assist with the study-wide applications is one of the key factors behind the OCREB‘s success.
Julie has been part of the team at Scimega, since 2013. Her passion for the business stems from knowing its expert oncology clinical development services add distinct value to industry stakeholders at a time when it's needed most. As CEO, her vision is to secure the company's long term success by leveraging her in-depth industry expertise & business acumen.
Julie equates that success with setting a clear vision for the organization's continued sense of purpose. She is responsible for developing successful business strategies & leveraging industry opportunities all of which support the common vision she shares with her team. Julie's leadership & collaboration with the managing Board of Directors, esteemed colleagues with whom she has worked alongside for many years, ensure the business excellence upon which Scimega has built its reputation.
As CEO, Julie plays a vital role in promoting Scimega's expertise and showcasing Canada's attributes as a formidable partner in global oncology drug development.
Job Titles:
- Director, Clinical Operations
Marie-Claude has 25 years of oncology experience as a healthcare and clinical research professional. This includes an extensive & impressive track record in the conduct and oversight of multi-center global oncology clinical trials. Marie-Claude, who has been part of the Scimega team since 2016, is responsible for Clinical Operations. In her leadership role, Marie-Claude is dedicated to ensuring the operations team consistently produces stellar performance metrics, key to our clients' success. As a corporate Director, Marie-Claude is an active member of Scimega's managing Board of Directors.